ClinicalTrials.gov
ClinicalTrials.gov Menu

Optimization of Novel DCE-MRI Imaging Sequences for Cancer Therapy Monitoring

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01752231
Recruitment Status : Terminated (Feasibility issues.)
First Posted : December 19, 2012
Last Update Posted : December 21, 2017
Sponsor:
Information provided by (Responsible Party):
City of Hope Medical Center

December 12, 2012
December 19, 2012
December 21, 2017
July 23, 2013
August 29, 2017   (Final data collection date for primary outcome measure)
Dynamic contrast-enhanced MRI (DCE-MRI) as a measure of tumor treatment response. [ Time Frame: 1 year ]
Analysis of DCE-MRI data will be by semi-quantitative metrics such as the area under the curve (AUC), the slopes of contrast agent uptake and washout curves as well as peak contrast agent uptake. Alternatively quantitative metrics based upon pharmacokinetic modeling will be derived. The model is the 2-compartment Kety model from which volume transfer constants between compartments and volume of the tissue compartments can be calculated.
Same as current
Complete list of historical versions of study NCT01752231 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Optimization of Novel DCE-MRI Imaging Sequences for Cancer Therapy Monitoring
Optimization of Novel DCE-MRI Imaging Sequences for Cancer Therapy Monitoring
This pilot clinical trial studies dynamic contrast enhanced (DCE)-magnetic resonance imaging (MRI) in diagnosing cancer. New diagnostic procedures, such as DCE-MRI may help find and diagnose cancer

PRIMARY OBJECTIVES:

I. Optimize and develop functional DCE-MRI pulse sequences, which involve the injection of MRI-visible contrast agents, for imaging in the head/neck, abdominal and pelvic regions.

II. Determine the ideal radiofrequency (RF) coil setup to maximize signal to noise ratio of the optimized pulse sequences.

III. Distill the findings of specific aims 1 and 2 into streamlined protocols that can be used in subsequent studies for cancer phenotyping and treatment monitoring in a quantitative manner.

IV. To establish a virtual reference image repository for future studies.

OUTLINE: Patients undergo DCE-MRI over approximately 30-60 minutes consisting of an anatomical scout image to localize the region of interest, a set of pre-injection scans to calibrate the dynamic image set, a dynamic image set during which contrast agent will be injected, and a set of post-injection scans to calibrate the DCE-MRI database.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Normal volunteers
Normal Volunteers
Not Provided
DCE-MRI (dynamic contrast-enhanced MRI)
Patients undergo DCE-MRI over approximately 30-60 minutes consisting of an anatomical scout image to localize the region of interest, a set of pre-injection scans to calibrate the dynamic image set, a dynamic image set during which contrast agent will be injected, and a set of post-injection scans to calibrate the DCE-MRI database.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
1
30
August 29, 2017
August 29, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

All subjects are eligible except for the following special cases:

Exclusion Criteria:

  • Female subjects who are or may be pregnant will NOT be eligible.
  • The minimum age for all subjects is 18 years old. No subjects under the age of 18 shall be considered.
  • If subject has received an imaging contrast agent of any kind within the past 7 days, they shall not be included in the study.
  • Subjects for whom MRI is contraindicated as set forth by the City of Hope Department of Radiology. These include:

    • electrical implants such as cardiac pacemakers or perfusion pumps
    • ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants
    • ferromagnetic objects such as jewelry or metal clips in clothing
    • pre-existing medical conditions, including a likelihood of developing seizures or anxiety disorders such as claustrophobia, panic attacks or any psychiatric disorder
    • any greater than normal potential for cardiac arrest
    • any subject with known kidney insufficiency function as evidenced by an abnormal serum creatinine (normal = 0.6 - 1.5 mg/dL) from a blood test performed on the subject within the past 6 months of the study date.
    • Any subject with abnormal creatinine clearance (normal = 100-130 ml/min/1.73m2), as measured by a direct test or from plasma creatinine (14) levels shall be excluded.
  • Normal subjects with a history of severe claustrophobia will not be eligible.
  • For ease of recruiting and study management purposes, only subjects who can give consent in English shall be eligible for this study.
Sexes Eligible for Study: All
18 Years to 100 Years   (Adult, Older Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01752231
12050
NCI-2012-03002 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
Yes
Not Provided
Not Provided
City of Hope Medical Center
City of Hope Medical Center
Not Provided
Principal Investigator: Jinha Park, MD, Ph.D. City of Hope Medical Center
City of Hope Medical Center
December 2017